Q2 2026 saw 11% local currency growth, strong margins, and robust net profit, aided by a $3M U.S. tariff refund. Prosthetics & Neuro Orthotics excelled with 12% organic growth, while Patient Care faced regional challenges. Guidance narrowed to 5%-7% growth, with a 22% EBITDA margin target.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.